Acute Limb Ischaemia (ALI) is a condition characterised by a rapidly decreased lower limb blood flow due to acute occlusion of a peripheral artery. It is a highly dangerous situation for the human body as, in the worst of cases, it can result in the loss of a limb or even lead to death. During the COVID-19 pandemic, the number of patients with ALI has increased significantly. The circulatory system is among the many systems that can be affected by COVID-19. By entering the human body, the SARS-CoV-2 virus disrupts the renin-angiotensin-aldosterone system, initiating a storm of cytokines and various processes which contribute to the formation of micro and macro clots. The diagnosis is formulated based on clinical symptoms, Duplex Doppler Ultrasound, Angio-CT, and DSA. Once ALI is identified, the patient should be immediately transferred to a specialized unit, where the appropriate treatment will be taken. Endovascular or surgical treatment is considered depending on the patient’s general condition, the anatomical location, and the Rutherford classification. Immediate and accurate assessment and well-executed intervention are key to saving the patient’s limb. Any delay or errors accompanying the diagnosis and treatment might lead to irreversible ischaemic damage. The aim of this paper is to summarise the current state of knowledge surrounding the impact of COVID-19 disease on the occurrence of ALI. The presented information and data may contribute to increasing awareness among healthcare professionals regarding the pathogenesis, diagnosis, and treatment of ALI.

Key words: Acute Limb Ischemia, COVID-19, SARS-CoV-2 virus, arterial thrombosis, blood clotting problems.